It purchased 4 million doses from Turkey and 5 million doses from China.
Potential disadvantages are the need for adjuvants to boost the immune response, handling of large quantities of live virus, and the verification of the integrity of antigens or epitopes.
All participants received at least one dose of the vaccine or placebo.
The Company is seeking market authorization of its products in over 30 countries outside of China.
From vaccines to memory and back.
In Indonesia, real world data from 128,290 healthcare workers showed 94% protection against symptomatic infection by the vaccine, beating results in clinical trials.